4-乙氧基甲基吡唑 | 1027618-59-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-乙氧基甲基吡唑
• 英文名称: 4-ethoxymethylpyrazole
• 英文别名: 4-(ethoxymethyl)-1H-pyrazole
• CAS: 1027618-59-2
• 化学式: C₆H₁₀N₂O
• 分子量: 126.158
• InChiKey: CCRKSEGEATVWQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-乙氧基甲基吡唑 在 四丁基溴化铵 、 sodium carbonate 作用下， 以 氯仿 、 水 为溶剂， 反应 72.0h， 以73%的产率得到tris(4-ethoxymethylpyrazolyl)methane
  参考文献：
  名称：

  Re(I) and 99mTc(I) tricarbonyl complexes with ether-containing pyrazolyl-based chelators: Chemistry, biodistribution and metabolism

  摘要：

  Tris(pyrazolyl) methane chelators, L1-L3, containing one or two ether groups at different positions of the azole rings, were synthesized and fully characterized. These chelators enabled the synthesis of fac[Tc-99m(CO)(3){HC[4-(ROCH2) pz](3)}] _ (R = Me (Tc1), Et (Tc2)) and fac-[Tc-99m(CO)(3){HC[3,5-(EtOCH2)(2)pz](3)}](+) (Tc3) which were identified by HPLC in comparison with the rhenium counterparts. The evaluation of Tc1 -Tc3 in CD-1 mice has shown that the number and/ or nature of the ether groups greatly influence the biodistribution profile, pharmacokinetics and metabolic stability of these complexes. Tc1 and Tc2, bearing a unique ether substituent at the 4-position of the pyrazolyl ring, undergo metabolic transformation in vivo while Tc3 is not metabolized. The metabolization of Tc1 and Tc2 enhanced their rate of excretion but, most probably, also justify their negligible heart uptake in contrast with the high heart uptake of congener non-metabolizable complexes (Tc-99m-DMEOP and Tc-99m-TMEOP), which have recently emerged as potential myocardial imaging agents. The attempts made to identify the metabolites of Tc1 and Tc2 have shown that the metabolization of these compounds must involve the ether functions with probable formation of carboxylic acid derivatives. A comparative study with the congener fac-[Tc-99m(CO)(3){[4-(MeOCH2)pz](CH2)(2)NH(CH2)(2)NH2}](+) (Tc6) led us to confirm the formation of such type of metabolites. In fact, Tc6 is also metabolized in mice with formation of fac-[Tc-99m(CO)(3){[4-(HOCH2)pz](CH2)(2)NH(CH2)(2)NH2}](+) (Tc7) and fac-[Tc-99m(CO)(3){[4-(HOOC) pz](CH2)(2)NH(CH2)(2)NH2}](+) (Tc8), which were chemically identified by HPLC in comparison with the Re congeners (Re7 and Re8). (C) 2013 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jorganchem.2013.11.013
• 作为产物：
  描述：

  1-trityl-4-ethoxymethylpyrazole 在 二氯甲烷 、 magnesium sulfate 作用下， 以 Acetone ethanol 、 盐酸 为溶剂， 反应 2.0h， 以yielding compound 4-ethoxymethylpyrazole as a white oil的产率得到4-乙氧基甲基吡唑
  参考文献：
  名称：

  Tricarbonyl Complexes with Tridentate Chelators for Myocardium Imaging

  摘要：

  公式（I）、（II）和（III）的螯合剂，以及与它们结合的Tc和Re放射性同位素的三羰基配合物，用于心肌成像。

  公开号：

  US20130131327A1

文献信息

• [EN] SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS<br/>[FR] DÉRIVÉS DE PIPÉRIDINYL-PYRIDAZINYLE SUBSTITUÉ UTILES COMME INHIBITEURS DE SCD 1
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2013085957A1

  公开（公告）日：2013-06-13

  The present invention is directed to novel piperidinyl-pyridazinyl derivatives, pharmaceutical compositions containing them and their use as inhibitors of SCD1, useful in the treatment of obesity, type-II diabetes and other related metabolic disorders.

  本发明涉及新型哌啶基-吡啶嗪衍生物，包括含有它们的制药组合物以及它们作为SCD1抑制剂的用途，有益于治疗肥胖症、2型糖尿病和其他相关代谢紊乱。
• [EN] IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE<br/>[FR] COMPOSÉS DE DIOXYDE D'IMINOTHIADIAZINE COMME INHIBITEURS DE BACE, COMPOSITIONS ET LEUR UTILISATION
  申请人：SCHERING CORP

  公开号：WO2011044181A1

  公开（公告）日：2011-04-14

  In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): (I) and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R1, R2, R3, R4, R5, R9, ring A, ring B, m, n, p, -L1-,L2-, and L3- is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (Aβ) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimers disease, are also disclosed.

  在其多种实施方式中，本发明提供了某些亚氨基噻二嗪二氧化物化合物，包括化合物式(I)的化合物和其立体异构体，以及所述化合物立体异构体的药学上可接受的盐，其中每个R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、L2-和L3-都是独立选择并在此定义。该发明的新型亚氨基噻二嗪二氧化物化合物出人意料地表现出具有优势的BACE抑制剂特性和/或用于治疗和预防与β-淀粉样蛋白（Aβ）产生相关的各种病理的特性。还公开了包括一种或多种这样的化合物（单独和与一种或多种其他活性剂的组合）的制药组合物，并揭示了在治疗与淀粉样β（Aβ）蛋白相关的病理，包括阿尔茨海默病中使用它们的方法。
• Technetium-99m (I) Tricarbonyl Complexes with Tridentate Chelators for Myocardium Imaging
  申请人：Santos Isabel Rego

  公开号：US20100074842A1

  公开（公告）日：2010-03-25

  Chelators of the formulae (I), (II) and (III) and tricarbonyl complexes of radioisotopes of Tc and Re bound to them, for use in myocardial imaging.

  公式（I）、（II）和（III）的螯合剂及与它们结合的Tc和Re同位素的三羰基配合物，用于心肌成像。
• Technetium-99m (I) tricarbonyl complexes with tridentate chelators for myocardium imaging
  申请人：Santos Isabel Rego

  公开号：US08372379B2

  公开（公告）日：2013-02-12

  Chelators of the formulae (I), (II) and (III) and tricarbonyl complexes of radioisotopes of Tc and Re bound to them, for use in myocardial imaging.

  公式（I），（II）和（III）的螯合剂以及与它们结合的Tc和Re的放射性同位素的三羰基配合物，用于心肌成像。
• Tricarbonyl Complexes with Tridentate Chelators for Myocardium Imaging
  申请人：Mallinckrodt LLC

  公开号：US20130129620A1

  公开（公告）日：2013-05-23

  Chelators of the formulae (I), (II) and (III) and tricarbonyl complexes of radioisotopes of Tc and Re bound to them, for use in myocardial imaging.

  公式（I），（II）和（III）的螯合剂及与它们结合的Tc和Re放射性同位素的三羰基配合物，用于心肌成像。